A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines

Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study

(2018) Clare L. Cutland et al.   VACCINE

Antibody persistence and booster response 68 months after vaccination at 2–10 years of age with one dose of MenACWY-TT conjugate vaccine

(2018) Markus Knuf et al.   VACCINE

Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010–2015

(2018) Sydel R. Parikh et al.   VACCINE

Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study

(2018) Ghassan Dbaibo et al.   VACCINE

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study

(2018) Wilbur H Chen et al.   LANCET INFECTIOUS DISEASES

Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – Results from a randomized, controlled, observer-blind phase II study

(2018) Jo Anne Welsch et al.   VACCINE

Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data

(2017) Caroline L Trotter et al.   LANCET INFECTIOUS DISEASES

Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants

(2017) Jose Manuel Merino Arribas et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine

(2017) Amanda C. Cohn et al.   PEDIATRICS

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

(2016) Sydel R Parikh et al.   LANCET

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

(2016) Roger Baxter et al.   Human Vaccines & Immunotherapeutics

Meningococcal serogroup B vaccines: Estimating breadth of coverage

(2016) Robert G. K. Donald et al.   Human Vaccines & Immunotherapeutics

Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays

(2015) Gregory A. Price et al.   CLINICAL INFECTIOUS DISEASES

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults

(2015) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial

(2015) Stan L. Block et al.   VACCINE

Serum bactericidal antibody assays – The role of complement in infection and immunity

(2015) E.D.G. McIntosh et al.   VACCINE

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents

(2014) Roger Baxter et al.   JOURNAL OF PEDIATRICS

Immunogenicity and Safety of a Meningococcal Serogroup A, C, Y and W Glycoconjugate Vaccine, ACWY-TT

(2013) Helen Findlow et al.   ADVANCES IN THERAPY

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

(2013) Miguel O’Ryan et al.   DRUGS

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial

(2013) Ghassan Dbaibo et al.   DRUGS & AGING

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study

(2013) Markus Knuf et al.   EUROPEAN JOURNAL OF PEDIATRICS

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

(2013) DM Daugla et al.   LANCET

One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children

(2013) Nicola P. Klein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

(2013) Giacomo Frosi et al.   VACCINE

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age

(2013) S. A. Halperin et al.   Journal of the Pediatric Infectious Diseases Society

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Meningococcal disease: Clinical presentation and sequelae

(2012) David Pace et al.   VACCINE

The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults

(2012) Mari Rose Aplasca-De Los Reyes et al.   Human Vaccines & Immunotherapeutics

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   Human Vaccines & Immunotherapeutics

Development of a group A meningococcal conjugate vaccine,MenAfriVacTM

(2012) Carl Frasch et al.   Human Vaccines & Immunotherapeutics

Measurement of Functional Anti-Meningococcal Serogroup A Activity Using Strain 3125 as the Target Strain for Serum Bactericidal Assay

(2011) Jan T. Poolman et al.   Clinical and Vaccine Immunology

Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis

(2011) Puiying A. Mak et al.   Clinical and Vaccine Immunology

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

(2011) Nancy Bermal et al.   Human vaccines & immunotherapeutics

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

(2011) Samba O. Sow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

(2011) Ziad A. Memish et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

(2011) Markus Knuf et al.   VACCINE

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial

(2011) Timo Vesikari et al.   VACCINE

Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source

(2011) C.J. Gill et al.   VACCINE

Meningococcal C conjugate vaccine: The experience in England and Wales

(2009) Helen Campbell et al.   VACCINE

Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera

(2008) D. M. Granoff et al.   INFECTION AND IMMUNITY